Citations

Clear

1792 citation(s) found for "Stephanie".

Management of recurrent and persistent metastatic lymph nodes in well‐differentiated thyroid cancer: A multifactorial decision‐making guide for the thyroid cancer care collaborative
Urken, Mark L. , Milas, Mira , Bergman, Donald A., Bernet, Victor , Brett, Elise M., Brierley, James D. , Cobin, Rhoda H., Doherty, Gerard M. , Klopper, Joshua , Macháč, Josef, Orloff, Lisa A. , Ross, Douglas S. , Smallridge, Robert C., Terris, David J. , Clain, Jason B. , Tuttle, Michael, Randolph, Gregory William , Tufano, Ralph Patrick , Lee, Stephanie J. , Mechanick, Jeffrey I.

Mayo Clinic

Head & Neck | January 17, 2014 | Volume: 37 | Issue: 4 | Pages: 605-614

10.1002/hed.23615 | PMID 24436291 Get It

AbstractBackgroundWell‐differentiated thyroid cancer (WDTC) recurs in up to 30% of patients. Guidelines from the American Thyroid Association (ATA) and the National Comprehensive Cancer Network (NCCN) provide valuable parameters for the management of recurrent disease, but fail to guide the clinician as to the multitude of factors that should be taken into account. The Thyroid Cancer Care Collaborative (TCCC) is a web‐based repository of a patient's clinical information. Ten clinical decision‐making modules (CDMMs) process this information and display individualized treatment recommendations.MethodsWe conducted a review of the literature and analysis of the management of patients with recurrent/persistent WDTC.ResultsSurgery remains the most common treatment in recurrent/persistent WDTC and can be performed with limited morbidity in experienced hands. However, careful observation may be the recommended course in select patients. Reoperation yields biochemical remission rates between 21% and 66%. There is a reported 1.2% incidence of permanent unexpected nerve paralysis and a 3.5% incidence of permanent hypoparathyroidism. External beam radiotherapy and percutaneous ethanol ablation have been reported as therapeutic alternatives. Radioactive iodine as a primary therapy has been reported previously for metastatic lymph nodes, but is currently advocated by the ATA as an adjuvant to surgery.ConclusionThe management of recurrent lymph nodes is a multifactorial decision and is best determined by a multidisciplinary team. The CDMMs allow for easy adoption of contemporary knowledge, making this information accessible to both patient and clinician. © 2014 Wiley Periodicals, Inc. Head Neck 37: 605–614, 2015
Guidelines for Application of Continuous Subcutaneous Insulin Infusion (Insulin Pump) Therapy in the Perioperative Period
Boyle, Mary E., Seifert, Karen M., Beer, K, Apsey, Heidi A., Nassar, Adrienne A., Littman, Stephanie D., Magallanez, Janice M., Schlinkert, Richard T., Stearns, Joshua D., Hovan, Michael J., Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 6 | Issue: 1 | Pages: 184-190

10.1177/193229681200600123 | PMID 22401338 Get It

Case reports indicate that diabetes patients receiving outpatient insulin pump therapy have been allowed to continue treatment during surgical procedures. Although allowed during surgery, there is actually little information in the medical literature on how to manage patients receiving insulin pump therapy during a planned surgical procedure. A multidisciplinary work group reviewed current information regarding the use of insulin pumps in the perioperative period. Although the work group identified safety issues specific to surgical scenarios, it believed that with the use of standardized guidelines and a checklist, continuation of insulin pump therapy during the perioperative period is feasible. A sample set of protocols have been developed and are summarized. A policy outlining clear procedures should be established at the institutional level to guide physicians and other staf if the devices are to be employed during the perioperative period. Additional clinical experience with the technology in surgical scenarios is needed, and consensus should be developed for insulin pump use in the perioperative phases of care.
Temporal and Geographic Patterns of Hypoglycemia among Hospitalized Patients with Diabetes Mellitus
Bailon, Rachel M., Hovan, Michael J., Hull, Bryan P., Seifert, Karen M., Miller-Cage, Victoria, Beer, K, Boyle, Mary E., Littman, Stephanie D., Magallanez, Janice M., Fischenich, Joanne M., Harris, Jana K., Scoggins, Susie S., Uy, Josephine, Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 3 | Issue: 2 | Pages: 261-268

10.1177/193229680900300206 | PMID 20144357 Get It

Background: Hypoglycemia is often cited as a barrier to achieving inpatient glycemic targets. We sought to characterize hypoglycemic events in our institution by work-shift cycle and by specific treatment area. Methods: Capillary (bedside) and blood (laboratory) glucose values of <70 mg/dl for patients with either a known diagnosis of diabetes or with evidence of hyperglycemia were abstracted from our laboratory database for hospitalizations between October 1, 2007, and February 3, 2008. Hypoglycemic events were analyzed by 12 h nursing work-shift cycles (day shift, 07:00 to 18:59; night shift, 19:00 to 06:59) and by the six medical, surgical, and intensive care areas in the hospital (designated areas 1 to 6). Results: We identified 206 individual patients with either diabetes or hyperglycemia (mean age, 67 years; 56% men; 83% white) who had 423 hypoglycemic events. There were 78% more hypoglycemic events during the night shift ( n = 271 events in 128 individual patients) than during the day shift ( n = 152 events in 96 individual patients). Most of the night-shift hypoglycemic measurements were detected between 04:00 and 04:59 or 06:00 and 06:59. The mean hypoglycemic level was comparable between shifts ( p = .79) and across the six inpatient areas. The number of hypoglycemic events per person increased with lengths of hospital stay >5 days. The prevalence of hypoglycemia varied across patient care areas within the hospital, with most (28%) detected in one area of the hospital. Conclusion: There are temporal and geographic patterns in the occurrence of hypoglycemia among patients with diabetes or hyperglycemia in our hospital. Further study should focus on the reasons underlying these variations so that specific interventions can address the risk of hypoglycemia during peak times and places.
Understanding and Improving Management of Inpatient Diabetes Mellitus: The Mayo Clinic Arizona Experience
Zimmerman, Richard S. , Gauthier, Susanne M., Castro, Janna C. , Jameson, Kimberly A. , Littman, Stephanie D., Magallanez, Janice M., Cook, Curtiss B.

Mayo Clinic

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 2 | Issue: 6 | Pages: 925-931

10.1177/193229680800200602 | PMID 19885281 Get It

We present an overview of strategies our institution has taken to understand the state of its inpatient diabetes management. We first describe how we utilized information systems to assess inpatient glycemic control and insulin management in noncritically ill patients and discuss our findings regarding mean bedside glucose levels, the prevalence and frequency hypoglycemic and hyperglycemic events, the patterns of insulin therapy, and evidence of inpatient clinical inertia. We also review the development of a survey to determine practitioner attitudes and beliefs about inpatient diabetes. Results of this survey study found that, in general, practitioners believed in the importance of controlling hyperglycemia but were not comfortable with many aspects of inpatient diabetes care, particularly with the use of insulin. Finally, we suggest steps to follow in developing a quality-improvement program for hospitals.
Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Weroha, S. John , Becker, Marc A., Enderica-Gonzalez, Sergio, Harrington, Sean C., Oberg, Ann L. , Maurer, Matthew J. , AlHilli, Mariam , Butler, Kristina , McKinstry, Sarah, Fink, Stephanie, Jenkins, Robert B. , Hou, Xiaonan , Kalli, Kimberly R., Goodman, Karin M., Hartmann, Lynn C. , Haluska, Paul , Perkins, Sarah E. , Sarkaria, Jann N. , Karlan, Beth Y. , Kumar, Amanika , Kaufmann, Scott H. , Maurer, Matthew

Mayo Clinic

Clinical Cancer Research | January 8, 2014 | Volume: 20 | Issue: 5 | Pages: 1288-1297

10.1158/1078-0432.ccr-13-2611 | PMID 24398046 Get It

Abstract Purpose: Ovarian cancer has a high recurrence and mortality rate. A barrier to improved outcomes includes a lack of accurate models for preclinical testing of novel therapeutics. Experimental Design: Clinically relevant, patient-derived tumorgraft models were generated from sequential patients and the first 168 engrafted models are described. Fresh ovarian, primary peritoneal, and fallopian tube carcinomas were collected at the time of debulking surgery and injected intraperitoneally into severe combined immunodeficient mice. Results: Tumorgrafts demonstrated a 74% engraftment rate with microscopic fidelity of primary tumor characteristics. Low-passage tumorgrafts also showed comparable genomic aberrations with the corresponding primary tumor and exhibit gene set enrichment of multiple ovarian cancer molecular subtypes, similar to patient tumors. Importantly, each of these tumorgraft models is annotated with clinical data and for those that have been tested, response to platinum chemotherapy correlates with the source patient. Conclusions: Presented herein is the largest known living tumor bank of patient-derived, ovarian tumorgraft models that can be applied to the development of personalized cancer treatment. Clin Cancer Res; 20(5); 1288–97. ©2014 AACR.
Airflow Obstruction, Lung Function, and Incidence of Atrial Fibrillation
Agarwal, Sunil , Alonso, Álvaro , Blecker, Saul , Chamberlain, Alanna M. , London, Stephanie J. , Loehr, Laura R. , McNeill, Ann , Poole, Charles, Soliman, Elsayed Z. , Heiss, Gerardo , Li, Jingjing, Li, Jingjing , Alonso, Alvaro , Chamberlain, Alanna M

Mayo Clinic

Circulation | December 16, 2013 | Volume: 129 | Issue: 9 | Pages: 971-980

10.1161/circulationaha.113.004050 | PMID 24344084 Get It

Background— Reduced low forced expiratory volume in 1 second (FEV 1 ) is reportedly associated with an increased risk of atrial fibrillation (AF). Extant reports do not provide separate estimates for never smokers or for blacks, who incongruously have lower AF incidence than whites. Methods and Results— We examined 15 004 middle-aged blacks and whites enrolled in the Atherosclerosis Risk in Communities (ARIC) cohort study. Standardized spirometry data were collected at the baseline examination. Incident AF was identified from the first among the following: International Classification of Diseases codes for AF on hospital discharge records or death certificates or 12-lead ECGs performed during 3 triennial follow-up visits. Over an average follow-up of 17.5 years, a total of 1691 participants (11%) developed new-onset AF. The rate of incident AF was inversely associated with FEV 1 in each of the 4 race and sex groups. After multivariable adjustment for traditional cardiovascular disease risk factors and height, hazard ratios of AF comparing the lowest with the highest quartile of FEV 1 were 1.37 (95% confidence interval, 1.02–1.83) for white women, 1.49 (95% confidence interval, 1.16–1.91) for white men, 1.63 (95% confidence interval, 1.00–2.66) for black women, and 2.36 (95% confidence interval, 1.30–4.29) for black men. The above associations were observed across all smoking status categories. Moderate/severe airflow obstruction (FEV 1 /forced vital capacity <0.70 and FEV 1 < 80% of predicted value) was also associated with higher AF incidence. Conclusions— In this large population-based study with a long-term follow-up, reduced FEV 1 and obstructive respiratory disease were associated with a higher AF incidence after adjustment for measured confounders.
Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation
Chow, Eric J. , Lee, Stephanie J. , Cushing‐Haugen, Kara L. , Inamoto, Yoshihiro , Khera, Nandita , Leisenring, Wendy M. , Syrjala, Karen L. , Baker, Kevin Scott , Flowers, Mary E.D. , Martin, Paul J. , Leisenring, Wendy , Chow, Eric J , Lee, Stephanie J

Mayo Clinic

Journal of Clinical Oncology | December 3, 2013 | Volume: 32 | Issue: 3 | Pages: 191-198

10.1200/jco.2013.52.6582 | PMID 24297944 Get It

Purpose To determine the influence of modifiable lifestyle factors on the risk of cardiovascular disease after hematopoietic cell transplantation (HCT). Patients and Methods HCT survivors of ≥ 1 year treated from 1970 to 2010 (n = 3,833) were surveyed from 2010 to 2011 on current cardiovascular health and related lifestyle factors (smoking, diet, recreational physical activity). Responses (n = 2,362) were compared with those from a matched general population sample (National Health and Nutrition Examination Survey [NHANES]; n = 1,192). Results Compared with NHANES participants, HCT survivors (median age, 55.9 years; median 10.8 years since HCT; 71.3% allogeneic) had higher rates of cardiomyopathy (4.0% v 2.6%), stroke (4.8% v 3.3%), dyslipidemia (33.9% v 22.3%), and diabetes (14.3% v 11.7%; P < .05 for all comparisons). Prevalence of hypertension was similar (27.9% v 30.0%), and survivors were less likely to have ischemic heart disease (6.1% v 8.9%; P < .01). Among HCT survivors, hypertension, dyslipidemia, and diabetes were independent risk factors for ischemic heart disease and cardiomyopathy, and smoking was associated with ischemic heart disease and diabetes (odds ratios [ORs], 1.8 to 2.1; P = .02). Obesity was a risk factor for post-transplantation hypertension, dyslipidemia, and diabetes (ORs ≥ 2.0; P < .001). In contrast, lower fruit/vegetable intake was associated with greater risk of dyslipidemia and diabetes (ORs, 1.4 to 1.8; P ≤ .01), and lower physical activity level was associated with greater risk of hypertension and diabetes (ORs, 1.4 to 1.5; P < .05). Healthier lifestyle characteristics among HCT survivors attenuated risk of all cardiovascular conditions assessed. Conclusion Attention of clinicians to conventional cardiovascular risk factors and modifiable lifestyle characteristics offers hope of reducing serious cardiovascular morbidity after HCT.
Diagnostic Exome Sequencing Identifies Two Novel IQSEC2 Mutations Associated with X‐Linked Intellectual Disability with Seizures: Implications for Genetic Counseling and Clinical Diagnosis
Gandomi, Stephanie, Gonzalez, Kelly, Parra, M., Shahmirzadi, Layla, Pichurin, Pavel N. , Temme, Renee, Dugan, Sarah, Mancuso, James J. , Zeng, Wenqi , Tang, Sha

Mayo Clinic

Journal of Genetic Counseling | December 3, 2013 | Volume: 23 | Issue: 3 | Pages: 289-298

10.1007/s10897-013-9671-6 | PMID 24306141 Get It

AbstractIntellectual disability is a heterogeneous disorder with a wide phenotypic spectrum. Over 1,700 OMIM genes have been associated with this condition, many of which reside on the X‐chromosome. The IQSEC2 gene is located on chromosome Xp11.22 and is known to play a significant role in the maintenance and homeostasis of the brain. Mutations in IQSEC2 have been historically associated with nonsyndromic X‐linked intellectual disability. Case reports of affected probands show phenotypic overlap with conditions associated with pathogenic MECP2, FOXG1, CDKL5, and MEF2C gene mutations. Affected individuals, however, have also been identified as presenting with additional clinical features including seizures, autistic‐behavior, psychiatric problems, and delayed language skills. To our knowledge, only 5 deleterious mutations and 2 intragenic duplications have been previously reported in IQSEC2. Here we report two novel IQSEC2 de novo truncating mutations identified through diagnostic exome sequencing in two severely affected unrelated male probands manifesting developmental delay, seizures, hypotonia, plagiocephaly, and abnormal MRI findings. Overall, diagnostic exome sequencing established a molecular diagnosis for two patients in whom traditional testing methods were uninformative while expanding on the mutational and phenotypic spectrum. In addition, our data suggests that IQSEC2 may be more common than previously appreciated, accounting for approximately 9 % (2/22) of positive findings among patients with seizures referred for diagnostic exome sequencing. Further, these data supports recently published data suggesting that IQSEC2 plays a more significant role in the development of X‐linked intellectual disability with seizures than previously anticipated.
Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
Grivas, Petros , Daignault, Stephanie, Tagawa, Scott T. , Nanus, David M. , Petrylak, Daniel P. , Vaughn, David J. , Bylow, Kathryn, Wong, Steven, Keller, Evan T. , Al‐Hawary, Mahmoud, Smith, David C. , Hussain, Maha , Stadler, Walter M. , Dreicer, Robert , Kohli, Manish , Sottnik, Joseph L. , Tagawa, Scott T , Hussain, Maha H A

Mayo Clinic

Cancer | November 18, 2013 | Volume: 120 | Issue: 5 | Pages: 692-701

10.1002/cncr.28477 | PMID 24249435 Get It

BACKGROUNDAngiogenesis contributes to the progression of urothelial carcinoma (UC). In the current study, the authors investigated the role of maintenance sunitinib in patients with advanced UC.METHODSPatients with locally recurrent/metastatic UC and adequate organ function who achieved stable disease or a partial or complete response after 4 to 6 chemotherapy cycles were randomized to sunitinib at a dose of 50 mg/day (28 days on and 14 days off) or placebo. The primary endpoint was the 6‐month progression rate. Secondary endpoints were safety, survival, change in serum vascular endothelial growth factor (VEGF)/soluble VEGF receptor‐2 (sVEGFR2), and the activity of sunitinib in patients who developed disease progression while receiving placebo. A total of 38 eligible patients per treatment arm were required to select better therapy with 90% probability (α = .05).RESULTSA total of 54 eligible patients were randomized to either the sunitinib arm (26 patients) or the placebo arm (28 patients). The median number of cycles received was 2 cycles per treatment arm. The most common grade 3 to 4 adverse events (graded according to version 3.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events) among patients receiving sunitinib were thrombocytopenia, diarrhea, mucositis, fatigue, and hypertension. There were no grade 3 or 4 adverse events noted among > 5% of patients receiving placebo. The 6‐month progression rate was 72% versus 64%. The median progression‐free survival (PFS) was 2.9 months (range, 0.5 months‐32.5 months) versus 2.7 months (range, 0.8 months −65 months) for the sunitinib versus placebo arms, respectively. Patients receiving placebo were found to have no changes in their serum VEGF/sVEGFR2 levels over time. Patients treated with sunitinib had no significant change in their VEGF level, but the sVEGFR2 level significantly decreased after cycles 1 and 2 (P < .0001) and at the time of disease progression (P = .0002). A baseline VEGF level that was at or greater than the median was found to be correlated with a longer PFS. Sixteen patients who were receiving placebo received sunitinib at the time of disease progression, with the best responses being 1 partial response (6.3%), 6 cases of stable disease (37.5%), and 5 cases of progressive disease (31.3%); 4 patients were not evaluable for response. The median PFS was 3.7 months (range, 0.1 months‐22 months).CONCLUSIONSThe current multicenter study was limited by premature closure and a small sample size. Maintenance sunitinib did not appear to improve the 6‐month progression rate. Open‐label sunitinib was found to have only modest activity. The sVEGFR2 level decreased among patients receiving sunitinib. Cancer 2014;120:692–701. © 2013 American Cancer Society.
The differential effects of dysarthria type on lexical segmentation.
Spitzer, Stephanie M., Caviness, John N., Liss, Julie , Lansford, Kaitlin L.

Mayo Clinic

The Journal of the Acoustical Society of America | October 28, 2013 | Volume: 125 | Issue: 4_Supplement | Pages: 2531-2531

10.1121/1.4783551 Get It

Although intelligibility deficits are common across various forms of dysarthria, it was hypothesized that the causes of intelligibility reductions depend on the ways the degraded signal challenges listener cognitive-perceptual strategies. This hypothesis was confirmed by analyzing the lexical boundary errors (LBE) elicited by 44 speakers with one of four forms of dysarthria (ataxic, hypokinetic, hyperkinetic, mixed spastic-flaccid). Error patterns from 60 listener transcripts revealed reliance on metrical stress to segment the 80 six-syllable phrases. However, reductions and disturbances in the acoustic cues to syllabic stress associated with each form of dysarthria resulted in different LBE patterns. Explanations for these unique patterns are found, in part, in the metrical structures of the dysarthric speech. For example, the temporal relationships among stressed and unstressed syllables varied widely in hyperkinetic speech, which ostensibly prevented listeners from optimally exploiting metrical stress as a cue for segmentation. The equal-even temporal structure of the spastic-flaccid speech resulted in the highest proportion of boundary insertions. The presence of interword pauses facilitated the assignment of word onset to strong syllables. Results will be presented relative to models of lexical segmentation and clinical implications for targets of remediation in the dysarthrias. [Work supported from NIH-NIDCD 5R01 DC6859.]